The reiteration of an Outperform rating and the maintenance of a $31 price target by a reputable analyst like Brian Abrahams from RBC Capital could positively influence investor sentiment towards Neumora Therapeutics. This endorsement suggests a strong belief in the company's potential for growth and profitability, likely leading to increased investor confidence and potentially driving up the stock price in the short term.